Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nuvectis Pharma, Inc. - Common Stock (NQ: NVCT )

4.950 -0.780 (-13.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nuvectis Pharma, Inc. - Common Stock

< Previous 1 2 Next >
Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort
Via AB Newswire
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
From Nuvectis Pharma, Inc.
Via GlobeNewswire
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
From PESG Research
Via Business Wire
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
From PESG Research
Via Business Wire
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Approaching Potentially Game-Changing Clinical Data: Nuvectis Pharma Reported Strong Q2 2024 Results (NASDAQ: NVCT)
Via AB Newswire
Nuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine Market
Via AB Newswire
Precision Medicine M&A is Transforming the Future of the Biotech Industry
Via AB Newswire
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma to Present at the 36th Annual Roth Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET 
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.